Virginia G. Kaklamani, MD, DSc, discusses datopotamab deruxtecan and other antibody-drug conjugates available for patients with unresectable or metastatic hormone receptor-positive, HER2-negative ...
Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/100.C0JpamNs.js ...
Zacks.com on MSN5h
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi DrugJ&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback